
Opinion|Videos|November 14, 2024
Current Challenges With Somatostatin Analogues in Neuroendocrine Tumors
Panelists discuss how somatostatin analogues, while effective in controlling hormone-related symptoms and tumor growth in neuroendocrine tumors, face challenges including drug resistance, optimal dosing strategies, and timing of initiation in the treatment sequence.
Advertisement
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Spotlighting the Top 10 FDA Oncology Approvals in 2025
2
A Look Back on the Top 10 Oncology Interviews in 2025
3
Zovegalisib Combo Confers Efficacy Benefit in PIK3CA-Mutated Breast Cancer
4
‘Relatively Low’ AEs Noted With Durvalumab/FLOT in Gastric/GEJ Cancer
5




